Marketed Products AndroGel® is the first-ever testosterone replacement gel to be approved by the FDA for replacement therapy in men for conditions associated with low testosterone. Low testosterone, also known as hypogonadism, affects approximately four to five million American men. The condition is linked to diminished interest in sex, impotence, reduced lean body mass, decreased bone density, lowered mood and increased fatigue. Androgens are contraindicated in men with carcinoma of the breast, or known or suspected carcinoma of the prostate. AndroGel® has not been clinically evaluated in males under 18 years of age. AndroGel® is not indicated for use in women, has not been evaluated in women, and must not be used in women. Pregnant women should avoid skin contact with AndroGel® application sites in men. Testosterone may cause fetal harm. Please see full prescribing information. Download PDF of AndroGel® prescribing information Link to AndroGel® Web Site. ANADROL®-50 is an anabolic-androgenic steroid for the treatment of anemia resulting from deficient production of red blood cells. ANADROL®-50 is the only oral anabolic-ancdrogenic steroid approved by the FDA to treat red blood cell deficiency anemias. ANADROL®-50 is contraindicated in: male patients with carcinoma of the prostate or breast; females with hypercalcemia with carcinoma of the breast; women who are or may become pregnant; patients with nephrosis or the nephrotic phase of nephritis; patients with hypersensitivity to the drug or with severe hepatic dysfunction. Warnings: peliosis hepatis, a condition in which liver and sometimes splenic tissue is replaced with blood-filled cysts, has been reported in patients receiving androgenic anabolic steroid therapy. Liver cell tumors are also reported. Most often these tumors are benign and androgen-dependant, but fatal malignant tumors have been reported. Blood lipid changes that are known to be associated with increased risk of atherosclerosis are seen in patients treated with androgens and anabolic steroids. Please see full boxed warning for more information on these conditions in the full prescribing information. View ANADROL®-50 prescribing information. Download PDF of ANADROL®-50 prescribing information MARINOL®, a synthetic formulation of delta-9-tetrahydrocannabinol, is approved as an appetite stimulant for HIV/AIDS patients and as an antiemetic to stem the nausea and vomiting associated with cancer chemotherapy. MARINOL® should be used with caution in patients with cardiac disorders, a history of substance abuse, mania, depression or schizophrenia. The Drug Enforcement Agency (DEA) rescheduled MARINOL® from Schedule II to Schedule III, a move that indicates a lower abuse potential for the product, and allows doctors to write refills for MARINOL®. Please see full prescribing information. Download PDF of MARINOL® prescribing information Link to MARINOL® Web Site. Corporate Overview | Unimed Products | Unimed News | Home